Friday, July 10, 2026

Drug profile · INN

influenza vaccine (split virion, inactivated)

influenza vaccine (split virion, inactivated) (INTANZA) is an FDA-listed pharmaceutical active ingredient.

EMA: withdrawn Antiinfectives for systemic use (J07) J07BB02
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — influenza vaccine (split virion, inactivated)
Class
Antiinfectives for systemic use (J07)
Route
Patents
0
Programs
2
Data quality
0.83

Quick answer

influenza vaccine (split virion, inactivated) (INTANZA) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN influenza vaccine (split virion, inactivated)
Brand INTANZA
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BB02

Approval history

Authority Status Date
EMA withdrawn

Pipeline programs

  1. PRO-QINF-3004 Phase 3 · Sinovac Research and · Seasonal Influenza
  2. PRO-QINF-4003 Approved · Sinovac Research and · Seasonal Influenza

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is influenza vaccine (split virion, inactivated)?

influenza vaccine (split virion, inactivated) (INTANZA) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for influenza vaccine (split virion, inactivated)?

INTANZA is a marketed brand name for influenza vaccine (split virion, inactivated). Check FDA Drugs@FDA for the current US label holder and prescribing information.